[go: up one dir, main page]

EE200300179A - Humaniseeritud LT-ß-R-i vastased antikehad - Google Patents

Humaniseeritud LT-ß-R-i vastased antikehad

Info

Publication number
EE200300179A
EE200300179A EEP200300179A EEP200300179A EE200300179A EE 200300179 A EE200300179 A EE 200300179A EE P200300179 A EEP200300179 A EE P200300179A EE P200300179 A EEP200300179 A EE P200300179A EE 200300179 A EE200300179 A EE 200300179A
Authority
EE
Estonia
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
EEP200300179A
Other languages
English (en)
Inventor
A. Garber Ellen
Lyne Paul
W. Saldanha Jose
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300179A publication Critical patent/EE200300179A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200300179A 2000-10-13 2001-10-12 Humaniseeritud LT-ß-R-i vastased antikehad EE200300179A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21
PCT/US2001/032140 WO2002030986A2 (en) 2000-10-13 2001-10-12 HUMANIZED ANTI-LT-β-R ANTIBODIES

Publications (1)

Publication Number Publication Date
EE200300179A true EE200300179A (et) 2003-08-15

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300179A EE200300179A (et) 2000-10-13 2001-10-12 Humaniseeritud LT-ß-R-i vastased antikehad

Country Status (25)

Country Link
US (2) US7429644B2 (et)
EP (1) EP1326897A2 (et)
JP (1) JP2004532608A (et)
KR (1) KR20030041164A (et)
CN (1) CN1547590A (et)
AR (1) AR035352A1 (et)
AU (2) AU2002211747B2 (et)
BG (1) BG107802A (et)
BR (1) BR0114646A (et)
CA (1) CA2425809A1 (et)
CZ (1) CZ20031307A3 (et)
EA (1) EA006945B1 (et)
EE (1) EE200300179A (et)
GE (1) GEP20063752B (et)
HU (1) HUP0302573A2 (et)
IL (1) IL155340A0 (et)
IS (1) IS6779A (et)
MX (1) MXPA03003144A (et)
NO (1) NO20031642L (et)
NZ (1) NZ525793A (et)
PL (1) PL366307A1 (et)
SK (1) SK5672003A3 (et)
TR (2) TR200602095T2 (et)
WO (1) WO2002030986A2 (et)
YU (1) YU28503A (et)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
BR0317573A (pt) * 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
JP2007530588A (ja) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
EA017303B1 (ru) * 2006-05-25 2012-11-30 Глаксо Груп Лимитед Модифицированные гуманизированные антитела против интерлейкина-18 и их применение
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
AR063257A1 (es) * 2006-10-12 2009-01-14 Genentech Inc Anticuerpos anti-linfotoxina alfa
NZ576424A (en) * 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CL2007003161A1 (es) 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
AR102521A1 (es) 2014-11-06 2017-03-08 Hoffmann La Roche Variantes de región fc con unión de fcrn modificada y métodos de utilización
JP6826113B2 (ja) * 2015-07-14 2021-02-03 イミューネクスト・インコーポレイテッド 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
IL293742A (en) * 2019-12-11 2022-08-01 Cilag Gmbh Int Multispecific binding molecules containing ltbr and edb binding sites and uses thereof
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
CN120882754A (zh) 2023-04-07 2025-10-31 瑞泽恩制药公司 用淋巴毒素β受体激动剂治疗癌症的方法
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE201879T1 (de) 1990-06-27 2001-06-15 Biogen Inc Oberflächenkomplexbildung von lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2150249A1 (en) 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
PL185364B1 (pl) * 1995-01-26 2003-04-30 Biogen Kompozycje farmaceutyczne do leczenia albo zmniejszenia zaawansowania, ciężkości albo skutków powstawania nowotworu
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ATE253930T1 (de) 1998-01-30 2003-11-15 Biogen Inc Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)- aktivierungsweges
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1539793A4 (en) 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
CA2511013A1 (en) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
BR0317573A (pt) 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos

Also Published As

Publication number Publication date
WO2002030986A3 (en) 2003-03-13
IL155340A0 (en) 2003-11-23
AU1174702A (en) 2002-04-22
CZ20031307A3 (cs) 2003-10-15
AU2002211747B2 (en) 2007-11-29
US20090092601A1 (en) 2009-04-09
EA006945B1 (ru) 2006-06-30
EA200300464A1 (ru) 2003-10-30
GEP20063752B (en) 2006-02-27
KR20030041164A (ko) 2003-05-23
EP1326897A2 (en) 2003-07-16
TR200602095T2 (tr) 2007-02-21
HUP0302573A2 (hu) 2003-10-28
JP2004532608A (ja) 2004-10-28
IS6779A (is) 2003-04-11
NO20031642D0 (no) 2003-04-10
WO2002030986A2 (en) 2002-04-18
TR200300478T2 (tr) 2004-10-21
AR035352A1 (es) 2004-05-12
US20040058394A1 (en) 2004-03-25
US7429644B2 (en) 2008-09-30
PL366307A1 (en) 2005-01-24
CA2425809A1 (en) 2002-04-18
MXPA03003144A (es) 2004-12-06
BR0114646A (pt) 2006-02-21
YU28503A (sh) 2006-05-25
BG107802A (bg) 2004-01-30
NO20031642L (no) 2003-06-13
SK5672003A3 (en) 2003-10-07
CN1547590A (zh) 2004-11-17
NZ525793A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IL156030A0 (en) Humanized antibodies
IS6982A (is) Mótefni gegn VLA-1
DK1501856T3 (da) Anti-HER2 antistofvarianter
NO20044347L (no) Anti-alfavbeta6-antistoff
IL166244A0 (en) Super humanized antibodies
IS2940B (is) Mótefni gegn CD40
DE50100900D1 (de) Fixierelement
EP1396500A4 (en) ANTI-TRAIL-R ANTIBODIES
DE10085449T1 (de) Fixiervorrichtung
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
NO20011006L (no) Höy-affinitets antistoffer
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
ITPD20000192A0 (it) Anticorpi policlonali
DE60135621D1 (de) Fixiergerät
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
DK1503799T3 (da) Immunogent, monoklonalt antistof
GB0029846D0 (en) Monoclonal antibody
GB0030139D0 (en) Monoclonal antibody
GB0003359D0 (en) Monoclonal antibodies
GB0008160D0 (en) Monoclonal antibodies
EA200201031A1 (ru) Двигательно-движительный комплекс

Legal Events

Date Code Title Description
HC1A Change of owner name